A unified cross-attention model for predicting antigen binding specificity to both HLA and TCR molecules

Read original: arXiv:2405.06653 - Published 5/14/2024 by Chenpeng Yu, Xing Fang, Hui Liu

📈

Overview

The paper proposes a new deep learning model called UnifyImmun that can simultaneously predict the binding of antigens to both HLA and TCR molecules, which are key components of the immune system.
This approach aims to provide a more comprehensive evaluation of antigen immunogenicity, or the ability of an antigen to trigger an immune response.
The model uses a two-phase progressive training strategy and incorporates virtual adversarial training to enhance its generalizability.
The authors demonstrate that UnifyImmun outperforms over ten existing methods for predicting antigen-HLA and antigen-TCR binding, particularly on a large-scale COVID-19 antigen-TCR binding test set.
Validation experiments on clinical cohorts confirm that UnifyImmun can effectively predict immunotherapy response and clinical outcomes.

Plain English Explanation

The immune system plays a crucial role in fighting against various types of cancer. One of the treatments that have shown promise in recent years are immune checkpoint inhibitors. These are drugs that help the immune system recognize and attack cancer cells more effectively.

However, not all patients respond to these treatments, and researchers are trying to understand why. One important factor is the interaction between the antigens (foreign substances) on cancer cells and the molecules in the immune system, such as HLA and TCR.

The paper proposes a new deep learning model called UnifyImmun that can predict how well an antigen will bind to both HLA and TCR molecules. This provides a more comprehensive assessment of the antigen's ability to trigger an immune response, which could help identify patients more likely to respond to immunotherapy.

The model uses a novel training strategy and incorporates techniques to improve its generalizability, meaning it can perform well on a wide range of data. Compared to existing methods, UnifyImmun demonstrates better performance in predicting antigen-HLA and antigen-TCR binding, particularly on a large COVID-19 dataset.

The researchers also show that UnifyImmun can effectively predict how patients will respond to immunotherapy and their clinical outcomes. Additionally, the model can identify the specific amino acid sites on the antigens that are critical for binding to the immune receptors, which could provide valuable insights for developing more effective cancer treatments.

Technical Explanation

The paper presents UnifyImmun, a unified cross-attention transformer model that can simultaneously predict the binding of antigens to both HLA and TCR molecules. This is a significant advancement over existing methods, which typically focus on predicting only one type of binding at a time.

The key innovation of UnifyImmun is its two-phase progressive training strategy, which compels the model's encoders to extract more expressive features by having the HLA and TCR binding prediction tasks reinforce each other. Additionally, the researchers incorporate virtual adversarial training to further enhance the model's generalizability.

Extensive experiments demonstrate that UnifyImmun outperforms over ten existing methods for predicting antigen-HLA and antigen-TCR binding, with particularly impressive results on a large-scale COVID-19 antigen-TCR binding test set. The authors also validate the model's performance on three clinical cohorts, confirming its ability to effectively predict immunotherapy response and clinical outcomes.

Moreover, the cross-attention scores generated by UnifyImmun reveal the specific amino acid sites on the antigens that are critical for binding to the HLA and TCR receptors. This information could be valuable for developing more effective cancer immunotherapies by targeting these key binding sites.

Critical Analysis

The paper presents a compelling approach to the challenge of predicting antigen immunogenicity, which is a crucial step in developing effective cancer immunotherapies. The authors' decision to tackle the simultaneous prediction of antigen-HLA and antigen-TCR binding is a significant advancement over existing methods, which have typically focused on only one of these tasks at a time.

One potential limitation of the study is the reliance on in silico (computer-simulated) data for training and evaluation. While the authors demonstrate the model's effectiveness on this data, it would be valuable to see how it performs on real-world clinical data, which may have different characteristics and challenges.

Additionally, the paper does not provide a detailed analysis of the computational complexity and training time requirements of the UnifyImmun model. This information would be helpful for assessing the feasibility of deploying the model in practical clinical settings, where processing speed and resource efficiency are often critical considerations.

Another area for further research could be exploring the potential of UnifyImmun to identify novel antigens or epitopes that could be targeted by cancer immunotherapies. The model's ability to reveal critical amino acid sites for binding could be leveraged to guide the discovery of new therapeutic targets.

Overall, the UnifyImmun approach represents an important step forward in the field of cancer immunotherapy research. The authors' emphasis on comprehensive evaluation of antigen immunogenicity and the model's strong performance on both in silico and clinical data are compelling. Continued development and validation of this technology could yield valuable insights and tools for improving the efficacy of cancer immunotherapies.

Conclusion

The paper presents a novel deep learning model, UnifyImmun, that can simultaneously predict the binding of antigens to both HLA and TCR molecules. This unified approach provides a more comprehensive evaluation of antigen immunogenicity, which is crucial for developing effective cancer immunotherapies.

The authors' innovative two-phase progressive training strategy and the incorporation of virtual adversarial training enable UnifyImmun to outperform over ten existing methods for predicting antigen-HLA and antigen-TCR binding. The model's strong performance, particularly on a large-scale COVID-19 dataset, and its ability to effectively predict immunotherapy response and clinical outcomes make it a promising tool for advancing cancer research and treatment.

Furthermore, the insights provided by UnifyImmun's cross-attention scores, which reveal the critical amino acid sites for antigen binding, could guide the discovery of new therapeutic targets and the design of more effective cancer immunotherapies. Overall, this research represents a significant step forward in the quest to harness the power of the immune system to fight cancer more effectively.

This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!

Follow @aimodelsfyi on 𝕏 →

Related Papers

📈

A unified cross-attention model for predicting antigen binding specificity to both HLA and TCR molecules

Chenpeng Yu, Xing Fang, Hui Liu

The immune checkpoint inhibitors have demonstrated promising clinical efficacy across various tumor types, yet the percentage of patients who benefit from them remains low. The binding affinity between antigens and HLA-I/TCR molecules plays a critical role in antigen presentation and T-cell activation. Some computational methods have been developed to predict antigen-HLA or antigen-TCR binding specificity, but they focus solely on one task at a time. In this paper, we propose UnifyImmun, a unified cross-attention transformer model designed to simultaneously predicts the binding of antigens to both HLA and TCR molecules, thereby providing more comprehensive evaluation of antigen immunogenicity. We devise a two-phase progressive training strategy that enables these two tasks to mutually reinforce each other, by compelling the encoders to extract more expressive features. To further enhance the model generalizability, we incorporate virtual adversarial training. Compared to over ten existing methods for predicting antigen-HLA and antigen-TCR binding, our method demonstrates better performance in both tasks. Notably, on a large-scale COVID-19 antigen-TCR binding test set, our method improves performance by at least 9% compared to the current state-of-the-art methods. The validation experiments on three clinical cohorts confirm that our approach effectively predicts immunotherapy response and clinical outcomes. Furthermore, the cross-attention scores reveal the amino acids sites critical for antigen binding to receptors. In essence, our approach marks a significant step towards comprehensive evaluation of antigen immunogenicity.

5/14/2024

Contrastive learning of T cell receptor representations

Yuta Nagano, Andrew Pyo, Martina Milighetti, James Henderson, John Shawe-Taylor, Benny Chain, Andreas Tiffeau-Mayer

Computational prediction of the interaction of T cell receptors (TCRs) and their ligands is a grand challenge in immunology. Despite advances in high-throughput assays, specificity-labelled TCR data remains sparse. In other domains, the pre-training of language models on unlabelled data has been successfully used to address data bottlenecks. However, it is unclear how to best pre-train protein language models for TCR specificity prediction. Here we introduce a TCR language model called SCEPTR (Simple Contrastive Embedding of the Primary sequence of T cell Receptors), capable of data-efficient transfer learning. Through our model, we introduce a novel pre-training strategy combining autocontrastive learning and masked-language modelling, which enables SCEPTR to achieve its state-of-the-art performance. In contrast, existing protein language models and a variant of SCEPTR pre-trained without autocontrastive learning are outperformed by sequence alignment-based methods. We anticipate that contrastive learning will be a useful paradigm to decode the rules of TCR specificity.

6/11/2024

↗️

Predicting T-Cell Receptor Specificity

Tengyao Tu, Wei Zeng, Kun Zhao, Zhenyu Zhang

Researching the specificity of TCR contributes to the development of immunotherapy and provides new opportunities and strategies for personalized cancer immunotherapy. Therefore, we established a TCR generative specificity detection framework consisting of an antigen selector and a TCR classifier based on the Random Forest algorithm, aiming to efficiently screen out TCRs and target antigens and achieve TCR specificity prediction. Furthermore, we used the k-fold validation method to compare the performance of our model with ordinary deep learning methods. The result proves that adding a classifier to the model based on the random forest algorithm is very effective, and our model generally outperforms ordinary deep learning methods. Moreover, we put forward feasible optimization suggestions for the shortcomings and challenges of our model found during model implementation.

7/30/2024

TCR-GPT: Integrating Autoregressive Model and Reinforcement Learning for T-Cell Receptor Repertoires Generation

Yicheng Lin, Dandan Zhang, Yun Liu

T-cell receptors (TCRs) play a crucial role in the immune system by recognizing and binding to specific antigens presented by infected or cancerous cells. Understanding the sequence patterns of TCRs is essential for developing targeted immune therapies and designing effective vaccines. Language models, such as auto-regressive transformers, offer a powerful solution to this problem by learning the probability distributions of TCR repertoires, enabling the generation of new TCR sequences that inherit the underlying patterns of the repertoire. We introduce TCR-GPT, a probabilistic model built on a decoder-only transformer architecture, designed to uncover and replicate sequence patterns in TCR repertoires. TCR-GPT demonstrates an accuracy of 0.953 in inferring sequence probability distributions measured by Pearson correlation coefficient. Furthermore, by leveraging Reinforcement Learning(RL), we adapted the distribution of TCR sequences to generate TCRs capable of recognizing specific peptides, offering significant potential for advancing targeted immune therapies and vaccine development. With the efficacy of RL, fine-tuned pretrained TCR-GPT models demonstrated the ability to produce TCR repertoires likely to bind specific peptides, illustrating RL's efficiency in enhancing the model's adaptability to the probability distributions of biologically relevant TCR sequences.

8/6/2024